吡咯替尼治疗铂类化疗后HER2突变晚期肺腺癌的II期研究
这项多中心、开放标签、单臂II期研究评估了吡咯替尼(400 mg/d)在60例既往接受铂类化疗的HER2突变晚期肺腺癌患者中的疗效与安全性。独立评审委员会评估的客观缓解率为30.0%(95%CI 18.8%–43.2%),中位无进展生存期和中位总生存期分别为6.9个月和14.4个月。3–4级治疗相关不良事件发生率为28.3%,最常见为腹泻(20.0%,均为3级),未报告治疗相关死亡。
要点
- 吡咯替尼在HER2突变晚期肺腺癌中客观缓解率达30.0%,各HER2突变亚型均显示获益。
- 有无脑转移患者的客观缓解率相似(25.0% vs 31.3%)。
- 3–4级不良事件以腹泻为主(20.0%),安全性总体可接受。
核心结论
- 吡咯替尼在经铂类化疗的HER2突变晚期非小细胞肺癌患者中显示出有前景的抗肿瘤活性和可接受的安全性。
研究设计与样本
- 前瞻性、多中心、开放标签、单臂II期研究,纳入60例既往接受铂类化疗的IIIB或IV期HER2突变肺腺癌患者。
- 吡咯替尼400 mg/d,21天为一周期,主要终点为独立评审委员会评估的客观缓解率。
主要发现
- 独立评审委员会评估的客观缓解率为30.0%(95%CI 18.8%–43.2%)。
- 中位缓解持续时间为6.9个月(95%CI 4.9–11.1个月)。
- 中位无进展生存期为6.9个月(95%CI 5.5–8.3个月),中位总生存期为14.4个月(95%CI 12.3–21.3个月)。
- 不同HER2突变类型亚组的客观缓解率均较好,有无脑转移患者客观缓解率相似(25.0% vs 31.3%)。
- 3–4级治疗相关不良事件发生率为28.3%,最常见为腹泻(20.0%,均为3级),未报告治疗相关死亡。
临床怎么用
- 对于既往铂类化疗失败的HER2突变晚期肺腺癌患者,吡咯替尼可作为潜在治疗选择,用药期间需重点监测腹泻。
局限性
- 单臂设计,无对照,样本量有限(60例),结论需随机对照研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Targeted therapies against non-small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of pyrotinib in patients with HER2-mutant advanced NSCLC in a prospective, multicenter, open-label, single-arm, phase II study. PATIENTS AND METHODS: Patients with stage IIIB or IV HER2-mutant lung adenocarcinoma who were previously treated with platinum-based chemotherapy were enrolled to receive pyrotinib at a dose of 400 mg/d for 21-day cycles. The primary end point was objective response rate per independent review committee (IRC). RESULTS: Between October 20, 2016, and December 10, 2018, 60 patients received pyrotinib monotherapy. At baseline, 58 (96.7%) were stage IV, and 25 (41.7%) received at least 2 lines of prior chemotherapy. As of data cutoff on June 20, 2019, IRC-assessed objective response rate was 30.0% (95% CI, 18.8% to 43.2%). All subgroups of patients with different HER2 mutation types showed a favorable objective response rate. The objective response rates were similar between patients with and without brain metastases (25.0% v 31.3%). The median duration of response was 6.9 months (95% CI, 4.9 to 11.1 months). The median progression-free survival was 6.9 months (95% CI, 5.5 to 8.3 months) per IRC. The median overall survival was 14.4 months (95% CI, 12.3 to 21.3 months). Treatment-related adverse events of grade 3 or 4 occurred in 28.3% of patients, with the most common being diarrhea (20.0%; all grade 3). No treatment-related deaths were reported. CONCLUSION: Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapy-treated patients with HER2-mutant NSCLC.
引用
- Zhou C, Li X, Wang Q, et al. Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2020. PMID: 32614698. doi:10.1200/JCO.20.00297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。